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Ark1, the unique Aurora kinase in Schizosaccharomyces pombe, regulatesmultiple aspects of mitosis. In this
issue ofChemistry & Biology, Kawashima and colleagues report the discovery and validation of a fungal Ark1
inhibitor, which they employ to evaluate the mitotic outputs of endogenous Ark1 signaling.Mitosis is a prime example of a dynamic
cellular transition orchestrated bymultiple
protein kinase activities. Untanglingwhich
kinases do what, and when and where
they do it, represents a major challenge
in the field. Unfortunately, we currently
lack validated tools to distinguish
between on/off (switch-like) and wide-
range (rheostat-like) catalytic outputs of
kinases, the latter potentially enabling
diverse cellular outputs to be spatially
and temporally programed using a single
enzyme. This question is pertinent to
cell-cycle regulated kinases such as
Mps1, Aurora, and Polo-like kinases,
which are reversibly activated during
mitosis and integrate the sequential steps
required to successfully execute cell divi-
sion (Bayliss et al., 2012). One technique
for studying kinase biology involves the
exploitation of small molecule inhibitors,
whose rapid and often reversible binding
to kinases can be successfully harnessed
to probe signaling in cells. However, to be
really effective as biological tools, these
compounds must inhibit a cellular kinase
target in a specific and/or highly tractable
fashion (Cohen, 2009). Unfortunately,
most protein kinase inhibitors are falliblein this regard, due to high promiscuity
toward multiple ATP-binding sites and
the complex challenges associated with
unequivocal ‘‘on-target’’ validation, which
is a widespread problem in molecular
pharmacology. However, because pro-
tein kinases contain prominent amino
acid loci whose physiochemical proper-
ties create ‘‘selectivity filters’’, the dis-
criminatory capacity of many kinases for
diverse compounds targeting the ATP
site can be rationalized in a rather general
manner (Balzano et al., 2011; Bishop
et al., 2000; Eyers et al., 1998; Huang
et al., 2010). Four key positions bordering
the hinge region of protein kinases dictate
resistance or sensitivity to differing
ligands, and we term these amino acids
a ‘‘resistance tetrad’’ (Figure 1). Critically,
catalytically silent mutation of these resi-
dues can create resistant (or sensitized)
versions of kinases, permitting pheno-
typic effects observed with small mole-
cules to be validated with high levels of
certainty (Balzano et al., 2011; Eyers
et al., 1999; Scutt et al., 2009; Sloane
et al., 2010; Zunder et al., 2008).
The fission yeast Schizosaccharomy-
ces pombe is a valuable laboratory modelfor studying mitosis. Unfortunately, it is
resistant to many small molecules that
traverse the cell membrane of vertebrate
cells, potentially restricting its usefulness
for mechanistic drug discovery. Two
recent studies reported in Chemistry &
Biology by the Nurse and Kapoor labora-
tories have addressed this major obstacle
to progress in the field. In their initial
paper, Kawashima et al. (2012) described
the generation of a drug-sensitive fission
yeast strain (MDR-sup) in which fivemulti-
drug resistance (MDR) genes were
deleted, enhancing the ability of small
molecules to accumulate and induce
quantifiable biological effects. Hot on the
heels of this advance, the same group
(Kawashima et al., 2013; in this issue
of Chemistry & Biology) reports the
discovery of Arkin-1 (Figure 1A), an inhib-
itor of the endogenous S. pombe kinase
Ark1, a key regulator of mitosis related
to vertebrate Aurora kinases (Petersen
et al., 2001). By combining a small mole-
cule screen with chemical genetics in
Ark1 wild-type and drug-resistant iso-
genic strains, evidence for rheostat-like
behavior of Ark1 during mitosis was
uncovered, which is consistent with the
Figure 1. Arkin-1 Is a Target-Validated Fungal Aurora Kinase
Inhibitor
(A) Chemical structures of VX-680 (Tozasertib) and Arkin-1, with prominent
chemical groups shaded in blue. The piperazine group of VX-680 (blue) lies
adjacent to G160 in the co-crystal structure with human Aurora B, and muta-
tion to bulkier amino acids induces drug-resistance, presumably due to steric
hindrance (Scutt et al., 2009). Based on this model, the equivalent G172
residue in Ark1 is likely to accommodate the N-7 pyridin-2-yl extension to
the pyrrolopyrimidine ring of Arkin-1 (blue), and mutation to larger amino acids
should induce phenotypic resistance in Aurora kinases to Arkin-1 and related
compounds (Kawashima et al., 2013; Moriarty et al., 2006).
(B) Alignment of amino acids in the ATP-binding site of fission yeast (Sp),
human (Hs) and baker’s yeast (Sc) Aurora kinases. Four key amino acids
make up the malleable resistance tetrad, corresponding to the four residues
labeled in the human Aurora B and VX-680 cocrystal structure, which is
derived from published coordinates (Protein Data Bank ID code 4AF3).
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phorylation catalyzed by
human Aurora B (Wang
et al., 2011).
In order to reach these
conclusions and target
‘‘endogenous’’ Ark1 (rather
than an artificial Ark1 mutant),
several challenges had to be
overcome. Initially, an in vitro
panel of small molecules that
inhibit recombinant human
and fungal Aurora kinases
was assembled. Surprisingly,
potent Aurora inhibitors such
as VX-680 (Figure 1A) dis-
played little effect on cellular
S10 phosphorylation of
histone H3 (a physiological
Ark1 phosphorylation site),
even when tested in an
MDR-sup strain. However,
by using an ingenious
‘‘synthetic-lethal’’ chemical
screen, the pyrrolopyrimidine
small molecule Arkin-1
(Figure 1A) was discovered.
Arkin-1 blocks Ark1 activity
in vitro, induces mitotic
phenotypes directly attribut-
able to its inhibition (including
effects on chromosome com-paction, nucleolar separation, and defec-
tive kinetochore-microtuble correction),
and is highly toxic toward the MDR1-sup
strain. One question raised by these find-
ings was if Arkin-1 induces these effects
through the predicted ‘‘on-target’’ (i.e.
Ark1-mediated) mechanism. To investi-
gate this question, nine drug-resistant
yeast clones were isolated from a chemi-
cally mutagenized strain exposed to
7.5 mM Arkin-1. Sequencing of Arkin-
resistant clones confirms an Ark1-depen-
dent inhibitory mechanism, because each
expresses a G172 point mutation in Ark1,
while exogenous expression of G172D
Ark1 induces biochemical and phenotypic
resistance to Arkin-1. No crystal structure
of Ark1 is available to confirm the Arkin-1
binding mode, but G172 is equivalent to
G160 in human Aurora B, a hinge-loop
amino acid that is part of the Aurora
kinase ‘‘resistance-tetrad’’ controlling
affinity toward inhibitors like VX-680
(Figure 1B). These new data are also
entirely consistent with previous work
describing drug-resistant human Aurora
A and B kinase alleles (Scutt et al.,2009). With the cellular target of Arkin-1
established, Kawashima et al. (2013)
investigated the effects of exposing yeast
strains to differing concentrations of
Arkin-1 by evaluating the dose-depen-
dence of phenotypes provoked by the
compound. Interestingly, a low dose
(2 mM) of Arkin-1 inhibits mitotic chromo-
some condensation, suggesting that
this process might require high levels of
Ark1 activity, whereas higher doses
(5 mM) reveal additional defects in spindle
checkpoint function, suggesting that
lower Ark1 activity is needed to success-
fully correct microtubule/kinetochore
interactions. The authors also provide
evidence that Ark1 activity regulates an
unknown chromosome compaction
factor in addition to the condesin subunit
Cnd2/Barren, because Arkin-1 still blocks
chromosome arm separation in the pres-
ence of a constitutively active cnd2-3E
mutant (Kawashima et al., 2013).
Taken together, these studies herald
a new era for empirical analysis of kinase
inhibitors in fission yeast, with the princi-
ples of this work transposable into otherChemistry & Biology 20, February 21, 2013 ª2013 Elsesystems where inhibitors are
employed to evaluate cell sig-
naling. Indeed, it is possible
that closer analysis of rheo-
stat-like signaling capabilities
among therapeutically rele-
vant protein kinases will
reveal the optimal levels of
catalytic blockade that are
essential for kinase inhibitors
to induce a desired cellular
phenotype or to provoke
a defined ‘‘on-target’’ clinical
response.
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